Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 5, 2020Consolidated Second Quarter Reported Net Sales up 6.1%; Organic(1) Net Sales Up 2.6%
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced financial results for the second quarter ended June 27, 2020. President and...
-
Jul 29, 2020
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.225 per...
-
Jul 15, 2020
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Self-Care Products, today announced that it will release its second quarter financial results on Wednesday, August...
-
Jun 19, 2020
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO) today announced the closing of the previously announced registered public offering by Perrigo Finance Unlimited Company, an...
-
Jun 19, 2020
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has reached a definitive agreement to sell its U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals...
-
Jun 17, 2020Partnership focuses on large scale production and supply of cGMP compliant, THC-free CBD
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it is entering the cannabidiol ("CBD") market through a strategic...
-
Jun 16, 2020
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced the pricing of a previously announced...
-
Jun 16, 2020
Perrigo Company plc ("Perrigo" or the "Company") (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that Perrigo Finance Unlimited Company, an...
-
Jun 2, 2020
Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will present further details on the Company's consumer growth strategy along with a general update...
-
May 8, 2020
Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will host a fireside chat at the RBC Capital Markets Global Healthcare Conference at 11:30 AM EDT on...
-
May 5, 2020
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.225 per...
-
May 5, 2020
Perrigo Company plc (NYSE; TASE: PRGO) today announced that President and CEO Murray S. Kessler will present as part of the Goldman Sachs Global Staples Forum Webcast at 8:10 AM EST on Monday, May...
-
Apr 30, 2020Reports Record First Quarter Consumer Self-Care Americas Net Sales
Perrigo Company plc (NYSE; TASE: PRGO) today announced financial results for the first quarter ended March 28, 2020. President and CEO Murray S. Kessler commented, "During these unprecedented...
-
Apr 22, 2020
The Perrigo Company plc (NYSE; TASE: PRGO) Board of Directors considers the well-being of shareholders, employees and service providers at the upcoming Annual General Meeting ("AGM") a primary...
-
Apr 16, 2020
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter financial results on Thursday, April 30, 2020. The Company will also host a conference call beginning...
-
Apr 7, 2020Q1 2020 net sales growth of 14% versus prior year quarter
Perrigo Company plc (NYSE; TASE: PRGO) announced today preliminary unaudited first quarter 2020 net sales and provided GAAP and non-GAAP operating income for the first quarter. Perrigo CEO and...
-
Apr 6, 2020
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it was the first to receive approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for...
-
Apr 2, 2020
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the oral self-care assets of High Ridge Brands. The acquisition underscores the numerous bolt-on...
-
Feb 27, 2020Reports Record Fourth Quarter Consumer Self-Care Americas Net Sales
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products™", today announced financial results for the fourth quarter and fiscal year ended...
-
Feb 24, 2020
Perrigo Company plc (NYSE; TASE: PRGO) and its partner, Catalent Pharma Solutions, today announced that the U.S. Food and Drug Administration (FDA) has approved Perrigo's abbreviated new drug...
-
Feb 24, 2020- Strengthens Perrigo's oral self-care leadership position with acquisition of the #1 and fastest growing value brand player in the children's oral care category
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has reached a definitive agreement to acquire the oral care assets of High Ridge Brands for $113 million in cash. The acquisition,...
-
Feb 18, 2020
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products™", today announced that its Board of Directors, consistent with its transformation...
-
Feb 13, 2020
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and calendar year 2019 financial results on Thursday, February 27, 2020. The Company will also host a...
-
Feb 7, 2020Jeff Needham to retire; Rich Sorota appointed to lead Consumer Self-Care Americas business
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced the future retirement of Jeff Needham, Executive Vice President and...
-
Jan 14, 2020
Perrigo Company plc (NYSE: PRGO) (TASE: PRGO) Chief Executive Officer and President Murray S. Kessler will highlight the progress of the Company's transformation into a consumer self-care company...
-
Jan 6, 2020- Expands robust oral self-care portfolio with opportunities for growth
Perrigo Company plc (NYSE; TASE: PRGO) announced today that its Ranir subsidiary has acquired the assets of Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush...
-
Dec 18, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler will present at the ICR Conference at 9:30 AM EST on Monday, January 13, 2020 at the Grande Lakes...
-
Dec 2, 2019
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the acquisition of the branded over-the-counter (OTC) rights to Prevacid®24HR. Jeff Needham, Executive Vice President...
-
Nov 13, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at...
-
Nov 6, 2019Continues Successful Transformation to a Consumer Self-Care Company
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care ProductsTM", today announced financial results for the third quarter ended September 28, 2019....
-
Nov 4, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21...
-
Oct 23, 2019
As a precautionary measure, Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack...
-
Oct 15, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a...
-
Oct 3, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and...
-
Sep 5, 2019- Expands U.S. OTC market and gastrointestinal category leadership positions
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid® from GlaxoSmithKline. Under the terms of the...
-
Aug 22, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples...
-
Aug 21, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc....
-
Aug 8, 2019
GAAP ("reported") net sales were $1.15 billion, reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased by approximately 1% excluding the unfavorable impact...
-
Aug 7, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief...
-
Jul 31, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21...
-
Jul 25, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference...
-
Jul 8, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million. Perrigo...
-
Jul 3, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug...
-
Jul 2, 2019- Advances transformation to a consumer-focused, self-care company
Perrigo Company plc (NYSE; TASE: PRGO) today announced the successful completion of its acquisition of Ranir Global Holdings LLC ("Ranir"), the leading global store brand supplier of oral...
-
Jun 21, 2019
Dublin, Ireland and Allegan, MI – June 21, 2019 – Perrigo Company plc is issuing a voluntary nationwide recall of 35-ounce, 992-gram containers of Parent’s Choice Advantage Infant Formula...
-
May 21, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA)...
-
May 9, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today is holding its Investor Day at the New York Stock Exchange in New York City, outlining its strategy to drive long-term growth and build shareholder...
-
May 9, 2019- All cash transaction valued at $750 million, or approximately $685 million inclusive of cash tax benefits on a present value basis
Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750...
-
May 8, 2019
GAAP ("reported") net sales were $1.2 billion, reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. First quarter reported diluted...
-
May 8, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (NASDAQ: PETQ) in a transaction valued at $185...
-
May 1, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss...
-
Apr 26, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that the company's Board of Directors, consistent with its recently approved strategic plan to evolve to a consumer self-care company,...
-
Apr 18, 2019
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced that it will hold its Investor Day on May 9 in New York City to...
-
Apr 4, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug...
-
Apr 2, 2019
Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its...
-
Mar 20, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ray Silcock will join the Company as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the...
-
Mar 18, 2019
Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™" today announced it has received tentative approval from the U.S. Food and Drug...
-
Mar 5, 2019
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Endo Pharmaceuticals Inc. initiated patent litigation on March 1, 2019 in the United States District Court for the District of Delaware...
-
Feb 27, 2019
Full-year 2018 GAAP ("Reported") net sales of $4.7 billion, reflecting a 4% decline versus a year ago; Fourth quarter 2018 reported net sales of $1.2 billion, a 7% decline versus the prior year....
-
Feb 25, 2019- Committed to vigorously challenge the Notice of Amended Assessment; believes it is without merit and incorrect as a matter of law
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced that its subsidiary, Perrigo Pharma International DAC ("Elan...
-
Feb 14, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.19...
-
Feb 13, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its...
-
Feb 13, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it will release its fourth quarter and calendar year 2018...
-
Feb 6, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jan 29, 2019
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality, Affordable Self-care Products™", today announced that the company expects to receive a milestone payment of $250...
-
Jan 14, 2019
Perrigo Company plc (NYSE, TASE: PRGO) today announced that James Dillard has been appointed Executive Vice President and Chief Scientific Officer. In this new role, Jim will be responsible for...
-
Dec 20, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that President and CEO Murray Kessler will present at the 37th Annual J.P. Morgan Global Healthcare Conference at 5:00 PM EST on Tuesday,...
-
Dec 10, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the...
-
Nov 28, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma...
-
Nov 27, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Solaraze® Gel, 3%...
-
Nov 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the first to file generic version of Ultravate® Lotion...
-
Nov 8, 2018
Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion, reported net loss of $68 million compared to a net income of $45 million last year and reported diluted loss per share of $0.49
-
Oct 31, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on December 18, 2018 to shareholders of record on...
-
Oct 29, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Anacor Pharmaceuticals, Inc., initiated patent litigation on October 25, 2018 in the United States District Court for the District of...
-
Oct 26, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on October...
-
Oct 25, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter calendar year 2018 financial results on Thursday, November 8, 2018. The Company will host a conference...
-
Oct 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Androgel® Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g...
-
Oct 8, 2018
Murray S. Kessler, former Chief Executive Officer and President at the Lorillard Tobacco Company, appointed President, CEO and member of the Board of Directors effective immediately Proven track...
-
Oct 1, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken...
-
Sep 28, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Picato® (ingenol mebutate) gel, 0.015%, 0.05% brought by LEO Pharma Inc., LEO...
-
Sep 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of...
-
Aug 29, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously...
-
Aug 9, 2018- Expands Consumer Healthcare Americas growth strategy with innovative offering for an Rx to OTC brand switch and store brand solution
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the...
-
Aug 9, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's...
-
Aug 9, 2018
Realized second quarter 2018 GAAP ("reported") net sales of $1.2 billion, reported net income of $36 million compared to a net loss of $70 million last year and reported diluted earnings per share...
-
Aug 1, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on September 18, 2018 to shareholders of record on...
-
Jul 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter calendar year 2018 financial results on Thursday, August 9, 2018. The Company will host a conference...
-
May 30, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the Jefferies 2018 Healthcare Conference at 8:30 AM EST on Tuesday,...
-
May 24, 2018
Perrigo Company plc (NYSE; TASE: PRGO) announced today that Promius Pharma LLC initiated patent litigation on May 22, 2018 in the U.S. District Court for the Eastern District of Texas, regarding...
-
May 14, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Sun Pharmaceutical Industries, Inc. and MiCal Pharmaceuticals LLC initiated patent litigations on May 9 and 10, 2018, in the U.S....
-
May 11, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it expects to receive a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its Abbreviated New Drug...
-
May 8, 2018
Realized first quarter 2018 GAAP ("reported") net sales of $1.2 billion, reported net income of $81 million compared to $72 million last year, an increase of 12.9%, and reported diluted earnings...
-
May 3, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on June 19, 2018 to shareholders of record on June 1, 2018.
-
Apr 24, 2018- Separately, the Company announced that it will present at the Deutsche Bank Healthcare Conference on May 9, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its first quarter calendar year 2018 financial results on Tuesday, May 8, 2018. The Company will host a conference call...
-
Apr 11, 2018- Consumer friendly dosing provides patients with needed heartburn alternative
Perrigo Company plc (NYSE; TASE: PRGO) and its partner Dexcel Pharma Technologies, Ltd., today announced the launch of store brand Omeprazole Delayed Release Orally Disintegrating Tablets 20mg...
-
Mar 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex® DM Maximum...
-
Mar 7, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ron Winowiecki, Perrigo Chief Financial Officer, will present at the 2018 Barclays Global Healthcare Conference at 1:35 PM EST on...
-
Mar 1, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission and...
-
Mar 1, 2018
Fourth Quarter Realized fourth quarter 2017 GAAP ("reported") net sales of $1.3 billion, reported net income of $73 million and reported diluted earnings per share ("EPS") of $0.52 compared to a...
-
Feb 27, 2018Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018
Select Preliminary Unaudited Calendar Year 2017 Results Delivered strong calendar year 2017 GAAP ("reported") and adjusted net sales at the high end of previous guidance range and operating cash...